Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3082 - Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): a pooled analisys of TRIBE and TRIBE-2 studies by GONO

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Emanuela Dell'Aquila

Citation

Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246

Authors

E. Dell'Aquila1, D. Rossini2, M. Stellato1, F. Bergamo3, G. Aprile4, F. Morano5, R. Intini3, E. Fea6, M. Ronzoni7, M. Libertini8, A. Buonadonna9, L. Fanchini10, L. Marcucci11, E. Maiello12, F. Marmorino2, A. Boccaccino2, S. Cordio13, G. Masi2, A. Falcone2, D. Santini1

Author affiliations

  • 1 Department Of Medical Oncology, Campus Bio-Medico University of Rome, 00128 - Rome/IT
  • 2 Department Of Translational Research And New Technologies In Medicine And Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, 56126 - Pisa/IT
  • 3 Medical Oncology Unit 1, Veneto Institute of Oncology IRCCS, 35128 - Padua/IT
  • 4 Department Of Oncology, University Hospital, 33100 - Udine/IT
  • 5 Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 6 Medical Oncology, Azienda Ospedaliera S Croce e Carle, 12100 - Cuneo/IT
  • 7 Medical Oncology, IRCCS San Raffaele, 20132 - Milan/IT
  • 8 Oncology Unit, Fondazione Poliambulanza, 25124 - Brescia/IT
  • 9 Department Of Clinical Oncology, Centro di Riferimento Oncologico (CRO) - IRCCS, 33081 - Aviano/IT
  • 10 Ssd Colorectal Cancer Unit Dipartimento Di Oncologia, AOU Città della Salute e della Scienza di Torino, 10126 - Turin/IT
  • 11 Department Of Oncology, Azienda USL Toscana Nord Ovest, 56025 - Pontedera/IT
  • 12 Oncology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 - San Giovanni Rotondo/IT
  • 13 S.c. Di Oncologia Medica, ARNAS Garibaldi, 95123 - Catania/IT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3082

Background

Obesity is associated with an increased risk of development and recurrence of colorectal cancer. The role of obesity in mCRC patients (pts) is still unclear, especially in those treated with triplet plus bevacizumab (bev). The aim of our study was to evaluate the prognostic and predictive role of BMI in mCRC pts treated with FOLFOXIRI plus bev or FOLFIRI/FOLFOX plus bev in the TRIBE and TRIBE-2 trial.

Methods

1160 pts enrolled in TRIBE and TRIBE-2 trials were included. Baseline height and weight were used to assign patients to one of the following BMI categories: underweight (group A = BMI <18.5 kg/m2; 52 pts), normal (group B= BMI 18.5–29.9 kg/m2; 952 pts) and obese (group C > 30 kg/m2; 156 pts).

Results

In our population, no differences in terms of PFS (p = 0.38) or OS (p = 0.93) resulted between three groups. No interaction effect between treatment arm and BMI was evident in terms of PFS (HR: 0.70 [95%CI: 0.40-1.22]; HR: 0.78 [95%CI: 0.68-0.89]; HR: 0.66 [95%CI: 0.48-0.91]; p for interaction= 0.61, in group A,B,C respectively) or OS (Group A HR: 0.62 [95%CI: 0.31-1.25]; Group B HR: 0.84 [95%CI: 0.72-0.98];Group C HR: 0.67 [95%CI: 0.46-0.99] p for interaction= 0.44). No statistically significant difference in terms of dose reductions due to toxicities were required according to BMI in overall population (p = 0.48) and in pts treated with FOLFOXIRI plus bev (p = 0.57).

Conclusions

BMI was not prognostic either for PFS or for OS in our population. Our analyses showed that the advantage of FOLFOXIRI plus bev versus FOLFIRI/FOLFOX plus bev was independent from BMI.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Daniele Santini.

Funding

Has not received any funding.

Disclosure

A. Falcone: Advisory / Consultancy, advisory board and Institutional funding to research: Amgen; Advisory / Consultancy, advisory board and Institutional funding to research: Roche; Advisory / Consultancy, advisory board and Institutional funding to research: Bayer; Advisory / Consultancy, advisory board and Institutional funding to research: Merck; Advisory / Consultancy, advisory board and Institutional funding to research: Servier; Advisory / Consultancy, advisory board and Institutional funding to research: Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.